| 1. |
- Djureinovic, Dijana, et al.
(författare)
-
Detection of autoantibodies against cancer-testis antigens in non-small cell lung cancer
- 2018
-
Ingår i: Lung Cancer. - : Elsevier BV. - 0169-5002 .- 1872-8332. ; 125, s. 157-163
-
Tidskriftsartikel (refereegranskat)abstract
- Cancer testis antigens (CTAs) are defined as proteins that are specifically expressed in testis or placenta and their expression is frequently activated in cancer. Due to their ability to induce an immune response, CTAs may serve as suitable targets for immunotherapy. The aim of this study was to evaluate if there is reactivity against CTAs in the plasma of non-small cell lung cancer (NSCLC) patients through the detection of circulating antibodies. To comprehensively analyse auto-antibodies against CTAs the multiplexing capacities of suspension bead array technology was used. Bead arrays were created with 120 protein fragments, representing 112 CTAs. Reactivity profiles were measured in plasma samples from 133 NSCLC patients and 57 cases with benign lung diseases. Altogether reactivity against 69 antigens, representing 81 CTAs, was demonstrated in at least one of the analysed samples. Twenty-nine of the antigens (45 CTAs) demonstrated exclusive reactivity in NSCLC samples. Reactivity against CT47A genes, PAGE3, VCX, MAGEB1, LIN28B and C12orf54 were only found in NSCLC patients at a frequency of 1%-4%. The presence of autoantibodies towards these six antigens was confirmed in an independent group of 34 NSCLC patients.In conclusion, we identified autoantibodies against CTAs in the plasma of lung cancer patients. The reactivity pattern of autoantibodies was higher in cancer patients compared to the benign group, stable over time, but low in frequency of occurrence. The findings suggest that some CTAs are immunogenic and that these properties can be utilized as immune targets.
|
|
| 2. |
- Hoffman, Tove, et al.
(författare)
-
Diagnostic Potential of a Luminex-Based Coronavirus Disease 2019 Suspension Immunoassay (COVID-19 SIA) for the Detection of Antibodies against SARS-CoV-2
- 2021
-
Ingår i: Viruses. - : MDPI. - 1999-4915. ; 13:6
-
Tidskriftsartikel (refereegranskat)abstract
- Due to the current, rapidly increasing Coronavirus disease 2019 (COVID-19) pandemic, efficient and highly specific diagnostic methods are needed. The receptor-binding part of the spike (S) protein, S1, has been suggested to be highly virus-specific; it does not cross-react with antibodies against other coronaviruses. Three recombinant partial S proteins of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) expressed in mammalian or baculovirus-insect cells were evaluated as antigens in a Luminex-based suspension immunoassay (SIA). The best performing antigen (S1; amino acids 16-685) was selected and further evaluated by serum samples from 76 Swedish patients or convalescents with COVID-19 (previously PCR and/or serologically confirmed), 200 pre-COVID-19 individuals (180 blood donors and 20 infants), and 10 patients with acute Epstein-Barr virus infection. All 76 positive samples showed detectable antibodies to S1, while none of the 210 negative controls gave a false positive antibody reaction. We further compared the COVID-19 SIA with a commercially available enzyme immunoassay and a previously evaluated COVID-19 rapid antibody test. The results revealed an overall assay sensitivity of 100%, a specificity of 100% for both IgM and IgG, a quantitative ability at concentrations up to 25 BAU/mL, and a better performance as compared to the commercial assays, suggesting the COVID-19 SIA as a most valuable tool for efficient laboratory-based serology.
|
|
| 3. |
- Källman, Mikael, et al.
(författare)
-
Use of CAM among cancer patients : results of a regional survey in Sweden
- 2023
-
Ingår i: BMC Complementary Medicine and Therapies. - : BioMed Central (BMC). - 2662-7671. ; 23:1
-
Tidskriftsartikel (refereegranskat)abstract
- Background: The use of complementary and alternative medicine (CAM) by patients is widespread. However, there is a lack of knowledge regarding the extent and details of patient CAM use in Sweden, especially in rural Sweden. The aim of this study was to estimate the extent and characteristics of CAM use among cancer patients in Region Gävleborg. Methods: A total of 631 questionnaires were distributed to which 376 responses were registered, yielding a response rate of 59.6%. Questionnaires were distributed to oncology patients at their first visit for curative treatment at the Department of Oncology, Gävle Hospital. Palliative patients were recruited at their first visit and during enrollment in palliative outpatient care in their own homes. The characteristics of the respondents were presented with standard descriptive statistics. A multivariable logistic model was fitted to calculate odds ratios (ORs) and identify potential predictors (Age, Gender, Education, Diagnosis) of CAM use post-cancer diagnosis. Results: 54% of all participants reported lifetime CAM use, 34% reported CAM use post-diagnosis. The most common CAM methods used after diagnosis are vitamins, health food preparations, herbal teas, prayer and dietary methods. The most common source of information reported is family and friends. Almost 70% of those who used CAM after their diagnosis stated that they did not discuss their use with healthcare professionals. Most patients reported that they would like some CAM modalities to be offered within conventional care regardless of their own CAM use. Conclusions: The use of CAM is common among patients with cancer in the region of Gävleborg, and previous studies show a similar use in Sweden in general. Based on the widespread use of CAM and patient interest in discussing CAM use with healthcare professionals, greater attention and focus should be placed on creating a basis for this dialogue. If we, as healthcare professionals, are to emphasise our commitment to providing patient-centred care, we must acknowledge that patients use CAM and are seeking a dialogue about CAM use in their care.
|
|
| 4. |
- Osterberg, Johanna, et al.
(författare)
-
[Abdominal sarcomas--rare tumors requiring multidisciplinary approach. Evaluation of surgical management in a sarcoma team].
- 2002
-
Ingår i: Läkartidningen. - 0023-7205 .- 1652-7518. ; 99:6, s. 490-4
-
Tidskriftsartikel (refereegranskat)abstract
- Retroperitoneal sarcomas and gastrointestinal stromal tumors are rare malignant tumors with a high recurrence rate. Due to their localization, and to the fact that they give rise to non-specific symptoms, these tumors are usually large at diagnosis. From 1990 to 1998 thirty-one patients (16 men and 15 women, mean age 45 years; range 15-77 years) went through surgical treatment. Patients were evaluated by a team consisting of an oncologist, a pathologist, a radiologist and a surgeon both pre- and postoperatively. Forty-five operations were performed (23 for primary tumors and 22 for recurrences). The resectability and radical resection rate were 89% and 59% respectively in primary tumors (4 patients with benign histological diagnoses were excluded) and 68% and 47% respectively in local recurrences. Other organs were removed in 50% of the procedures. Vascular and orthopedic surgeons participated when necessary. Morbidity and in-hospital mortality were 18% and 7% respectively. The overall recurrence rate was 70%. It is our belief that a multidisciplinary approach is mandatory for optimal treatment in these patients.
|
|
